Nature Reviews Drug Discovery
@NatRevDrugDisc
Editorial team of Nature Reviews Drug Discovery.
You might like
Wonderful summary resource from @CancerResearch @ay_zhou et al: The global landscape of cancer cell therapies, clinical trial trends and emerging directions nature.com/articles/d4157… @NatRevDrugDisc
For readers interested in bispecific antibodies as cancer therapies, here's a review rdcu.be/eOONr nature.com/articles/s4157…
Innovative antibody therapeutic development in China compared with the USA and Europe nature.com/articles/d4157… Data indicate that China’s focus on policy-driven innovation is enabling companies based there to surpass those in the USA and Europe in ADC and bispecific development
Cancer cell therapies: global clinical trial trends and emerging directions nature.com/articles/d4157… This new article by authors @CancerResearch analyses trends across trial phases, indications, modalities, cell sources and targets to map the current trajectory of the field
For readers interested in the development of drugs for fibrotic diseases such as idiopathic pulmonary fibrosis, here's a review discussing the underlying biology and how to address the translational research challenges rdcu.be/eOpGH nature.com/articles/s4157…
FDA approves PDE4 inhibitor for idiopathic pulmonary fibrosis nature.com/articles/d4157… Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
Induced proximity-based therapeutic modalities nature.com/articles/s4157… rdcu.be/eOfBH This new Review discusses the rapidly expanding landscape of therapeutic approaches based on inducing proximity between proteins, including targeted protein degraders and more
For readers interested in drugs for chronic obstructive pulmonary disease, affecting proteins such as IL-33 and TSLP that are targeted by the bispecific involved in Roche's $1 billion deal with Qyuns Therapeutics, here's a review rdcu.be/eN4SK nature.com/articles/s4157…
Roche turns to China's Qyuns for preclinical respiratory asset in over $1B deal $RHHBY firstwordpharma.com/story/6511061
For readers interested in synthetic lethality in cancer drug discovery, which has led to drug candidates such as vopimetostat, here's a recent review rdcu.be/eNFxC nature.com/articles/s4157…
$TNGX waltzes towards phase 3 with vopimetostat oncologypipeline.com/apexonco/node/… $BMY
Our November issue is live! Read more about drugs for cancer cachexia, RNA chemistry and therapeutics, targeting the Hippo pathway in cancer, the changing landscape of medicinal chemistry optimization and more here nature.com/nrd/volumes/24…
For readers interested in new drugs for chronic obstructive pulmonary disease, here's a comprehensive review rdcu.be/eNiYv nature.com/articles/s4157…
GSK’s Respiratory Pipeline Adds an Early-Stage Drug Offering a Novel Approach to COPD medcitynews.com/2025/10/gsk-re…
For readers interested in the potential to target particular protein isoforms as a way to achieve greater drug specificity, here's a review rdcu.be/eNiHj nature.com/articles/s4157…
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety nature.com/articles/s4157… rdcu.be/eM8hs This new Perspective discusses QST models for multiple organs and provides recommendations for building and applying them
Microfluidics, microelectronics, and microscaffolds are revolutionizing immunotherapy research, boosting patient outcomes in diverse cancer and autoimmune treatments. PMID:40954236, Nat Rev Drug Discov 2025, @NatRevDrugDisc doi.org/10.1038/s41573… #AI #Pharma #BioMed #RNA #ASHG…
For readers interested in drugs for Duchenne muscular dystrophy such as the antibody-oligonucleotide conjugate being developed by Avidity Biosciences, here's a review rdcu.be/eMW5A nature.com/articles/s4157…
Novartis plans to pay $12B in cash to buy Avidity Biosciences, and its three neuromuscular drugs that could head to the FDA next year. endpoints.news/novartis-to-bu…
For readers interested in new approach methodologies for assessing the safety of drug candidates, here's a Perspective from an EFPIA expert group rdcu.be/eMzJ3 nature.com/articles/s4157…
United States Trends
- 1. Sunderland 80.4K posts
- 2. St. John 4,655 posts
- 3. Texas Tech 9,232 posts
- 4. Obamacare 170K posts
- 5. Mendoza 7,959 posts
- 6. #iufb N/A
- 7. Letang N/A
- 8. Elyiss Williams N/A
- 9. Shapen N/A
- 10. Merino 7,745 posts
- 11. Mississippi State 3,654 posts
- 12. #SUNARS 5,390 posts
- 13. #GoDawgs 2,850 posts
- 14. #SaturdayVibes 5,687 posts
- 15. Xhaka 6,933 posts
- 16. Oscar Delp N/A
- 17. Aden Holloway N/A
- 18. Philon N/A
- 19. #BYUFOOTBALL N/A
- 20. Djokovic 9,339 posts
You might like
-
Nature Reviews Cancer
@NatureRevCancer -
Feng Zhang
@zhangf -
Nature Medicine
@NatureMedicine -
Nature Communications
@NatureComms -
Nature Biotechnology
@NatureBiotech -
Cell
@CellCellPress -
Cell Reports
@CellReports -
Nature Chemical Biology
@nchembio -
NatureRevClinOncol
@NatRevClinOncol -
Nature Methods
@naturemethods -
Molecular Cell
@MolecularCell -
Nature Rev Immunol
@NatRevImmunol -
Nature Cancer
@NatureCancer -
Nature Reviews Molecular Cell Biology
@NatRevMCB -
Nature News & Views
@NatureNV
Something went wrong.
Something went wrong.